Conference Coverage

CAR-T cells drive ALL into remission

Publish date: December 26, 2013

 

AT ASH 2013

Dr. Lee’s study was supported by the National Cancer Institute and St. Baldrick’s Foundation. He discussed off-label use of CAR-T cells. Dr. Lee reported having no conflicts of interest. Dr. Davila’s study was supported by MSKCC. He reported having no conflicts of interest.

Pages

Recommended Reading

Drug shortages affect prescribing for 83% of oncologists
MDedge Pediatrics
Late cord clamping may benefit infants, review suggests
MDedge Pediatrics
VTE rate triples in pediatric cancer survivors
MDedge Pediatrics
Cranial radiotherapy for acute lymphoblastic leukemia linked to impaired neurocognition
MDedge Pediatrics
Cord blood transplants improve juvenile myelomonocytic leukemia survival
MDedge Pediatrics
Pazopanib shows promise as pediatric sarcoma therapy
MDedge Pediatrics
Vitamin K deficiency bleeding in infants tied to insufficient parent knowledge of risks
MDedge Pediatrics
Resurrected gemtuzumab shows benefit against pediatric AML
MDedge Pediatrics
Gene therapy for SCID-X1 may successfully reset immune system
MDedge Pediatrics
Sickle cell crises curtailed with experimental cellular adhesion inhibitor
MDedge Pediatrics